Array, Pierre Fabre Partner On Cancer | Chemical & Engineering News
Volume 93 Issue 46 | p. 15 | Concentrates
Issue Date: November 23, 2015

Array, Pierre Fabre Partner On Cancer

Department: Business
Keywords: pharmaceuticals, biotech, oncology, MEK inhibitor

Pierre Fabre will pay Array BioPharma $30 million up front for the right to develop two cancer compounds, binimetinib and encorafenib, in Europe, Asia, and Latin America. In December, Array regained the rights to binimetinib, a MEK inhibitor in Phase III trials in ovarian cancer and melanoma, from Novartis, which had to divest the compound as a condition of acquiring GlaxoSmithKline’s oncology business. Novartis later sold Array the rights to encorafenib, a BRAF inhibitor in Phase III studies in ovarian cancer. Pierre Fabre will pay for 40% of future development costs of the two drugs.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment